Asahi Kasei has concluded a license agreement
with Schering AG of Germany for its orally administered fasudil,
which holds strong promise for treatment of angina pectoris.
Background and purpose of agreement
The development by Asahi Kasei of fasudil for the treatment
of ischemia has led to approval in Japan of an injection formulation
for cerebral vasospasm and to clinical trials conducted in
Japan of an oral formulation for treatment of angina pectoris.
The injection formulation, trademarked
Eril® Injection S, has been approved and is currently
marketed in Japan, with sales of approximately 1.3 billion
yen in fiscal 2000. Eril® Injection S is indicated for
improvement of cerebral vasospasm following surgery for subarachnoid
hemorrhage and associated cerebral ischemic symptoms.
Phase II clinical trials have been completed in Japan to confirm
the efficacy of an orally administered formulation for the
treatment of angina pectoris. In the light of its promise
and the related needs for such therapy, the license agreement
with Schering AG has now been concluded for its clinical development
in Europe and North America.
Essentials of the agreement
| • |
Licensed
pharmaceutical: Fasudil for oral administration. |
| • |
Licensee:
Schering AG of Germany. |
| • |
Scope
of license: Exclusive development and marketing worldwide
except for Japan, South Korea, China, and Taiwan. |
| • |
Initial
program: Advancement of clinical development in Europe
and North America for treatment of angina pectoris with
fasudil for oral administration by Schering AG. |
Schering AG, in brief corporate profile
Schering AG is a research-based pharmaceutical company. Its
activities are focused on four business areas: Fertility Control
and Hormone Therapy, Diagnostics and Radiopharmaceuticals,
Dermatology as well as Therapeutics for disabling diseases,
e.g. multiple sclerosis, leukemia and solid tumors. As a global
player with innovative products Schering AG aims for leading
positions in specialized markets worldwide. With in-house
R&D and supported by an excellent global network with external
partners, Schering AG is securing a promising product pipeline.
Using new ideas, Schering AG aims to make a recognized contribution
to medical progress and strives to improve the quality of
life.
www.schering.de
|
